Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Summary of the Cecchi patent application...as paid for

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
TempePhil Member Profile
 
Followed By 3
Posts 244
Boards Moderated 0
Alias Born 05/18/18
160x600 placeholder
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/20/2020 4:32:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:38:56 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
PURA BUY Recommendation at $0.03 Issued By AmericanBulls InvestorsHub NewsWire - 2/7/2020 10:33:33 AM
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 2/6/2020 7:00:10 AM
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference GlobeNewswire Inc. - 2/4/2020 7:00:10 AM
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Developmen... GlobeNewswire Inc. - 2/3/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 GlobeNewswire Inc. - 1/30/2020 7:00:10 AM
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 6:00:00 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
TempePhil   Monday, 03/25/19 09:00:08 PM
Re: nidan7500 post# 186759
Post # of 238012 
Summary of the Cecchi patent application...as paid for by Anavex(applicant).
Thanks nidan for posting the link to the Cecchi patent app.

I am intrigued by the testing that the inventor Cecchi discusses. He describes a lot of the dosing and testing that this board questioned and guessed about, several months back.
He also gives measures of 2-73 efficacy, and the data, which are interesting as measures against current SOC, and whether 2-73 is really effective!
I always like data, because it is the science that proves 2-73 efficacy or not. And Cecchi describes more than I have seen before for 2-73.
Here are my notes from the patent for anyone that is interested. I paraphrased a lot and summarized. Many of the comments in parentheses are my comments or questions. I like to not only compare 2-73 to normal AD patients, but also to know how much 2-73 has moved the patient back to normal. So I sometimes calculated this value myself below.

Disclaimer...Use my notes at your own risk!

Definitions
DSC Differential Scanning Calorimeter
EEG ElectroEncephalograph -used to access effects for 2-73
ERP Event Related Potentials - Voltage changes locked to some physical occurence (ex.like hearing a tone).
PAF Peak Alpha Frequency - An EEG measurement. AD patients have reduce PAF which correlates to reduced cognitive performance.
P300 A battery of tests measuring patient response to audible tones.


Efficacy tests had 2-73 administered for 36 days to 12 patients with mild to moderate AD as an add-on therapy to patients that were already on donepezil(the current SOC).
Doses were alternately given to each patient both orally and intravenously. The oral doses were 30mg or 50mg and the IV dose was 3mg or 5mg.

ERPs as measured via an EEG provide a sensitive and accurate measure of the cognitive effects of early AD, and was used to assess the efficacy of 2-73.

Here baseline refers to the patients measurements before dosing.
Auditory P300 testing measures patient EEG response to audible tones. Used a COGNISION (Neuronetrix) headset. (Nothing special I think.)

The ERP waveform for the 12 patients, after 36 days on 2-73, more closely resembled healthy subjects. This is seen in figure 5.

Figure 6 and table 1, show the auditory P300 amplitude data for the baseline AD patient, the 36 day 2-73 patient, and a control (healthy) patient. The 2-73 patient shows a 38% improvement over baseline, and (my calc) is 73% back to normal! (wow!)

Table 2, show the button pressing data for the baseline AD patient, the 36 day 2-73 patient, and a control (healthy) patient. This is some type of button response test.
The data shows the 2-73 patients accuracy was only very slightly better than baseline. (Statistically in the noise?)
The data shows the 2-73 patients false alarms were nearly two times better than normal control. (This seems very suspect to me. How is it better than normal?)
The data shows the 2-73 patients reaction time improved 43% back to normal (my calc).

Figure 7 compares the P300 amplitude performance of a control group, a 2-73 group(12 patients 36 days) and a donepezil group(published data).
After one month the 2-73 group is a little better than the donepezil group, but at 1 month (versus donepezils slightly worse meaurement at 6 months). More importantly, both are improving over the control group.

The claims, the heart of the patent, are just about administering A2-73 at different doses and time intervals.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist